Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
| ▸ | IL1RN | P18510 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726433 | 0.89 | CA12 (0.55) | CA12CA9HTTSMN1; SMN2LMNA | |
| SCHEMBL6073367 | 0.87 | CA12 (0.72) | CA12CA9HTTSMN1; SMN2LMNA | |
| SCHEMBL6048148 | 0.86 | CYP19A1 (0.65) | HTTSMN1; SMN2LMNAPKMMAPK1 | |
| SCHEMBL28864522 | 0.86 | LMNA (0.68) | CA12CA9HTTSMN1; SMN2LMNA | |
| SCHEMBL19598884 | 0.84 | TUBB4A (0.61) | CA12CA9HTTPKMALDH1A1 | |
| SCHEMBL5280989 | 0.84 | LMNA (0.55) | CA12CA9HTTSMN1; SMN2LMNA | |
| SCHEMBL6350411 | 0.84 | HTR6 (0.65) | CA9HTTSMN1; SMN2LMNAPKM | |
| SCHEMBL399122 | 0.84 | LMNA (0.77) | CA12CA9HTTSMN1; SMN2LMNA | |
| SCHEMBL6341219 | 0.83 | LMNA (0.79) | CA12CA9HTTSMN1; SMN2LMNA | |
| SCHEMBL19598900 | 0.82 | TUBB4A (0.58) | CA12CA9HTTHTR6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181269-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | claimed |
| EP-0610653-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1997-04-16 | — | — | EP | claimed |
| US-5444036-A | Arylsulfonylureido compound, acetoacetanilide compound, sulfonamide derivative; storage stability | NEW OIL PAPER CO., LTD. (JP) | 1995-08-22 | — | — | US | claimed |
| EP-0610653-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1994-08-17 | — | — | EP | claimed |
| US-7060718-B2 | Arylsulfonanilide ureas | AMGEN INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20030207864-A1 | Arylsulfonanilide ureas | TULARK INC. | 2003-11-06 | — | — | US | disclosed |
| US-6583165-B2 | Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents | TULARIK INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1115701-B1 | ARYLSULFONANILIDE UREAS | TULARIK INC (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1285911-A2 | Arylsulfonanilide ureas | Tularik Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1181269-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20010027211-A1 | Arylsulfonanilide ureas | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| EP-1115701-A1 | ARYLSULFONANILIDE UREAS | Tularik Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6214880-B1 | LOWERING PLASMA CHOLESTEROL LEVELS AND INHIBITING ABNORMAL CELL PROLIFERATION WITH SAID COMPOUND; TREATMENT OF CANCER, PSORIASIS, VASCULAR RESTENOSIS, INFECTIONS, ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA | TULARIK INC. | 2001-04-10 | — | — | US | disclosed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000017159-A1 | ARYLSULFONANILIDE UREAS | TULARIK INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0610653-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1997-04-16 | — | — | EP | disclosed |
| US-5444036-A | Arylsulfonylureido compound, acetoacetanilide compound, sulfonamide derivative; storage stability | NEW OIL PAPER CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0610653-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207864-A1 | Arylsulfonanilide ureas | UTS2R, UACA, UMPS | CA12 4752/4885CA9 3078/4885HTT 1350/4885 |
| US-20010027211-A1 | Arylsulfonanilide ureas | UTS2R, UACA, UMPS | CA12 4752/4885CA9 3078/4885HTT 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.